Evidence map›Paper›PMID 38042761›Full record

ReviewMolecular diversity2024

Investigating catalytic pathways: a comparative review of homogeneous and heterogeneous catalysis for 3-aroylimidazo[1,2-a]pyridine synthesis.

Mohamed Moutaouakil, Othmane Roby, Said Tighadouini, Abdelmjid Cherif, Abdelmalik El Aatiaoui, Rafik Saddik

Abstract readReviewComparative Study
PubMed Publisher
In one paragraph

Review in Molecular diversity, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Mohamed MoutaouakilLaboratory of Organic Synthesis, Extraction, and Valorization, Faculty of Sciences Ain Chock, Hassan II University, 20000, Casablanca, Morocco. mtk.med1@gmail.com.
Othmane RobyLaboratory of Organic Synthesis, Extraction, and Valorization, Faculty of Sciences Ain Chock, Hassan II University, 20000, Casablanca, Morocco.
Said TighadouiniLaboratory of Organic Synthesis, Extraction, and Valorization, Faculty of Sciences Ain Chock, Hassan II University, 20000, Casablanca, Morocco.
Abdelmjid CherifLaboratory of Materials Engineering for Environment and Valorization, Faculty of Sciences Ain Chock, Hassan II University, 20000, Casablanca, Morocco.
Abdelmalik El AatiaouiLaboratory of Molecular Chemistry, Materials and Environment (LCM2E), Department of Chemistry, Multidisciplinary Faculty of Nador, Mohamed I University, Nador, Morocco.
Rafik SaddikLaboratory of Organic Synthesis, Extraction, and Valorization, Faculty of Sciences Ain Chock, Hassan II University, 20000, Casablanca, Morocco.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

3-aroylimidazo[1,2-a]pyridines represent a class of derivatives in the imidazo[1,2-a]pyridine family known for their important biological and pharmaceutical activities. Consequently, various methodologies have been designed to simplify the synthesis of this structure, with an emphasis on the use of cost-effective starting materials and environmentally friendly protocols. All the methods developed in recent years (from 2016 to 2023) rely on homogeneous or heterogeneous catalysts. Therefore, we aim to perform a comparative analysis between these two approaches, elucidating their respective advantages and limitations. The first part of this work focuses on techniques employing homogeneous catalysts, followed by the next section devoted to heterogeneous catalysts. This comprehensive review should be of substantial interest to researchers in the fields of organic and medicinal chemistry, as it provides a valuable resource for their research.

Indexed as

PyridinesCatalysisChemistry Techniques, SyntheticImidazolesImidazolesPyridines2-aminopyridine3-aroylimidazo[1,2-a]pyridinesHeterogeneous catalystsHomogeneous catalystsImidazo[1,2-a]pyridine

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.